Related Experiment Video
Updated: Feb 3, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Immunotherapy in Gliomas
Objectives:
To describe the immunotherapy approaches currently under investigation for the treatment of gliomas. To discuss the management of immune-related adverse effects.
Data Sources:
Published literature, clinical trials, and oncology association guidance documents.
Conclusion:
There are numerous modalities of immune treatment currently being evaluated in patients with glioma, including peptide vaccines, dendritic cell vaccines, oncolytic viruses, CAR-T cells, and checkpoint inhibitor therapy. Immunotherapy utilizes new mechanisms of treatment that may lead us to the eradication of gliomas.
Implications For Nursing Practice:
Immunotherapy is a rapidly growing field in the treatment of gliomas. Oncology nurses are often involved in the safe administration of these therapies, as well as the identification and management of immune-related toxicities.
Insights
Immunotherapy offers novel treatment strategies for gliomas, with ongoing research into vaccines, oncolytic viruses, CAR-T cells, and checkpoint inhibitors. Understanding and managing immune-related side effects is crucial for patient care.
Area of Science:
- Oncology
- Immunology
- Neuro-oncology
Background:
- Gliomas are aggressive brain tumors with limited treatment options.
- Immunotherapy represents a promising frontier in glioma treatment.
- Oncology nurses play a vital role in managing novel cancer therapies.
Purpose of the Study:
- To review current immunotherapy approaches for glioma treatment.
- To discuss the management of immune-related adverse effects (irAEs).
Main Methods:
- Literature review of published studies.
- Analysis of clinical trial data.
- Examination of oncology association guidelines.
Main Results:
- Multiple immunotherapy modalities are under investigation for gliomas.
- These include peptide vaccines, dendritic cell vaccines, oncolytic viruses, CAR-T cells, and checkpoint inhibitors.
- Effective management strategies for irAEs are essential.
Conclusions:
- Immunotherapy holds significant potential for glioma eradication.
- Nurses require education on administering immunotherapies and managing irAEs.
